Article contents
A Monoamine Oxidase Inhibitor (Niamid) in the Treatment of the Mentally Subnormal
Published online by Cambridge University Press: 08 February 2018
Extract
A clinical evaluation of the effects of a recently introduced monoamine oxidase inhibitor, N - isonicotinoyl - N1—(β - N - benzylcarboxamido - ethyl) hydrazine (Niamid, Pfizer, Ltd.) on certain types of mentally subnormal patients has been carried out over the past year.
- Type
- Original Articles
- Information
- Copyright
- Copyright © Royal College of Psychiatrists, 1961
- 6
- Cited by
eLetters
No eLetters have been published for this article.